Interpace Z Score
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Please see Interpace Biosciences Piotroski F Score and Interpace Biosciences Valuation analysis.
Interpace Biosciences Invested Capital Average is projected to increase significantly based on the last few years of reporting. The past year's Invested Capital Average was at 11.06 Million. The current year Market Capitalization is expected to grow to about 33.2 M, whereas Return on Invested Capital is forecasted to decline to (1.48) . Interpace Biosciences Cost of Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Cost of Revenue was at 23.37 Million. The current year Interest Expense is expected to grow to about 718.9 K, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to (16.3 M).
Interpace  Z Score 
Interpace Z Score Analysis
Interpace Biosciences' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2019  2020  2021  2022 (projected)  
Interest Expense  440 K  549 K  496 K  718.95 K 
Gross Profit  8.33 M  10.72 M  17.95 M  15.16 M 
Z Score  =  Sum Of   5 Factors 
Current Interpace Biosciences Z Score  2.8 
Most of Interpace Biosciences' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Interpace Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Interpace Biosciences is extremely important. It helps to project a fair market value of Ford otc stock properly, considering its historical fundamentals such as Z Score. Since Interpace Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Interpace Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Interpace Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
According to the company's disclosures, Interpace Biosciences has a Z Score of 2.8. This is 141.48% lower than that of the Health Care Providers & Services sector and 184.08% lower than that of the Health Care industry. The z score for all United States stocks is 132.11% higher than that of the company.
Interpace Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in z score category among related companies.
Interpace Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Interpace Biosciences from analyzing Interpace Biosciences' financial statements. These drivers represent accounts that assess Interpace Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Interpace Biosciences' important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  (136.22 K)  (162.88 K)  (136.96 K)  (150.15 K)  (172.68 K)  (186.31 K)  
Revenue Per Employee  213.92 K  211.96 K  246.02 K  135.28 K  121.75 K  132.3 K  
Average Assets  51.18 M  46.35 M  57.73 M  54.44 M  41.44 M  51.19 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (5.93 M)  (12.3 M)  (11.66 M)  (26.17 M)  (30.09 M)  (32.47 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (8.49 M)  (8.55 M)  (21.8 M)  (20.35 M)  (9.74 M)  (10.51 M)  
Earnings before Tax  (12.61 M)  (12.69 M)  (26.77 M)  (26.4 M)  (15.61 M)  (16.84 M)  
Average Equity  34.29 M  32.45 M  21.43 M  (19.48 M)  (37.44 M)  (38.42 M)  
Enterprise Value  15.68 M  14.87 M  23.28 M  4.92 M  38.78 M  41.84 M  
Free Cash Flow  (15.29 M)  (9.12 M)  (19.07 M)  (15.55 M)  (9.03 M)  (9.75 M)  
Invested Capital  (2.8 M)  3.85 M  13.24 M  7.83 M  16.31 M  17.59 M  
Invested Capital Average  (4.2 M)  2.51 M  12.24 M  11.56 M  11.06 M  11.93 M  
Market Capitalization  27.39 M  22.88 M  19.1 M  12.69 M  31.18 M  33.16 M  
Tangible Asset Value  20.49 M  18.59 M  27.26 M  25.9 M  22.71 M  28.4 M  
Working Capital  11.72 M  9.05 M  (782 K)  (4.11 M)  (3.52 M)  (3.61 M) 
Interpace Fundamentals
Return On Equity  (2.85) %  
Return On Asset  (0.26) %  
Profit Margin  (0.59) %  
Operating Margin  (0.28) %  
Current Valuation  14.07 M  
Shares Outstanding  4.27 M  
Shares Owned by Insiders  28.12 %  
Number of Shares Shorted  47.35 K  
Price to Earning  (1.07) X  
Price to Book  10.04 X  
Price to Sales  0.13 X  
Revenue  41.31 M  
Gross Profit  17.95 M  
EBITDA  (9.12 M)  
Net Income  (14.94 M)  
Cash and Equivalents  1.86 M  
Cash per Share  0.44 X  
Total Debt  9.44 M  
Debt to Equity  6.55 %  
Current Ratio  0.61 X  
Book Value Per Share  0.42 X  
Cash Flow from Operations  (8.72 M)  
Short Ratio  0.19 X  
Earnings Per Share  (3.12) X  
Target Price  11.0  
Number of Employees  147  
Beta  0.79  
Market Capitalization  5.5 M  
Total Asset  38.43 M  
Retained Earnings  (172.59 M)  
Working Capital  (4.21 M)  
Current Asset  19.16 M  
Current Liabilities  23.37 M  
Z Score  2.8  
Net Asset  38.43 M 
About Interpace Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Interpace Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Interpace Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against riskreturn landscape of the market. 
All Next  Launch Module 
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Interpace Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Please see Interpace Biosciences Piotroski F Score and Interpace Biosciences Valuation analysis. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for analysis
When running Interpace Biosciences price analysis, check to measure Interpace Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Biosciences is operating at the current time. Most of Interpace Biosciences' value examination focuses on studying past and present price action to predict the probability of Interpace Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Biosciences' price. Additionally, you may evaluate how the addition of Interpace Biosciences to your portfolios can decrease your overall portfolio volatility.
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments  Go  
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account  Go  
Commodity Channel IndexUse Commodity Channel Index to analyze current equity momentum  Go  
Bond DirectoryFind actively traded corporate debentures issued by US companies  Go  
Equity ValuationCheck real value of public entities based on technical and fundamental data  Go  
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals  Go  
Portfolio BacktestingAvoid underdiversification and overoptimization by backtesting your portfolios  Go  
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios.  Go  
Focused OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences  Go  
Price TransformationUse Price Transformation models to analyze depth of different equity instruments across global markets  Go 